The Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment (PREDICT) Initiative
What is PREDICT?
The Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment (PREDICT) initiative empowers patients and doctors with the genetic information needed to anticipate and prevent adverse drug reactions or lack of effectiveness based on genetic information specific to each patient tested.
What is tested through PREDICT?
Using one blood test, patients are tested for more than 30 common genetic changes within several genes associated with drug metabolism or response. The PREDICT test is a clinical test, and PREDICT results are reported in the electronic health record and in MyHealthAtVanderbilt (MHAV). Only results for genes that have been reviewed and approved as actionable by Vanderbilt's Pharmacy and Therapeutics Committees are reported.
Genomics and Therapeutics Clinic
The Genomics and Therapeutics Clinic (GATC) was established at Vanderbilt University Medical Center (VUMC) in 2020 to help doctors and patients implement pharmacogenomics into clinical patient care. The clinic was founded by Sara Van Driest, MD, PhD, Associate Professor of Pediatrics and Medicine, and Andrea Ramirez, MD, MSCI, Assistant Professor of Medicine. Patients are seen by a physician provider with expertise in pharmacogenomics and Michelle Liu, PharmD, BCPS, a Board-Certified Pharmacotherapy Specialist. Dr. Liu joined VUMC in 2019 after completing a pharmacogenomics fellowship at Long Island University in Brooklyn, NY.
The GATC is a resource for physicians and patients who have questions about pharmacogenomic testing, including determinations of whether testing is appropriate or how best to apply test results to their medication plan. Both pediatric and adults patients are seen. The ultimate goal is to enhance medication efficacy and safety for patients through the appropriate use of pharmacogenomic testing.